Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Council Calls for Sharper Price Reductions for Long-Listed Drugs, Increase in Operating Profit Rate When Using Cost Calculation Method
August 26, 2013
- Applicants Objected to Proposed NHI Prices for 16 APIs in April 2010-May 2013; Revisions Made for 5 APIs
August 26, 2013
- First Committee Recommends Approval of Takeda’s Anti-Obesity Drug OBLEAN, Other Products
August 26, 2013
- Bill Payer and Healthcare Reps Support MHLW Proposal to Reduce NHI Prices; Industry Reps Want a Hold on a Decision
August 26, 2013
- Pharma Industry to Give Opinions at CSIMC Subcommittee in Sept., Stand against Health Ministry’s Plan to Cut Drug Prices
August 26, 2013
- CSIMC Sets No Prescription Limit for Irtra Combination Tablets
August 23, 2013
- CSIMC Approves Listing of 12 APIs, Parjeta Gets 5% Premium for Usefulness
August 23, 2013
- MHLW Proposes Plan to Downwardly Revise NHI Prices of Combination Drugs and Drugs Obtained as a Result of Optical Resolution of Racemic Bodies
August 23, 2013
- “Zero Risk” of Tumorigenicity from Products Using iPS Cells Cannot Be Guaranteed at Present: PMDA’s Science Board
August 23, 2013
- Health Ministry Notifies Prefectures of Approval for Xolair, Other Products
August 22, 2013
- MHLW to Draft New Guidance on Companion Diagnostics by End of 2013: Director Sato of ELD
August 20, 2013
- Takeda’s OBLEAN Joins Aug. 22 Review List of PAFSC 1st Committee
August 19, 2013
- 30-Plus Companies Gain Approval for Livalo, Valtrex Generics towards December Listing
August 16, 2013
- Case of Chagas Disease Confirmed through Blood Donation Raises Concern Over Secondary Infection
August 16, 2013
- 3 Ex-Officials of MHLW, NHO Affiliated with Novartis in 2010, Govt Says
August 15, 2013
- PMDA Meets All Targets for FY2012 with Exception of Time Spent by Applicants for Non-Priority Products
August 15, 2013
- Can Japan Become the Global Leader in Drug Discovery? New Vision for Pharmaceutical Industry Drops Company Categories Included in the Previous One
August 15, 2013
- PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
August 14, 2013
- MHLW Compiles Report on Expert Council on Future Cancer Research
August 14, 2013
- EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
August 13, 2013
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…